Details of Disease

General Information of Disease (ID: DIS2D4B9)

• Disease Name: Cystitis
• Synonyms: inflammation of urinary bladder; urinary bladder inflammation; bladder infection
• Disease Class: GC00: Cystitis
• Definition: Inflammation of the urinary bladder.
• Disease Hierarchy:
  DIS184KT: Skin inflammation
  DISTVIQI: Bladder disease
  DISWD40R: Disease
  DIS2D4B9: Cystitis
• ICD Code:
  ICD-11: ICD-11: GC00
  Expand ICD-11: 'GC00
  Expand ICD-10: 'N30; 'N30.4; 'N30.8; 'N30.9
• Disease Identifiers:
  MONDO ID: MONDO_0006032
  MESH ID: D003556
  UMLS CUI: C0010692
  MedGen ID: 8227
  HPO ID: HP:0100577
  SNOMED CT ID: 38822007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Betaine	DMGRZW2	Approved	Small molecular drug	[1]
Ciprofloxacin XR	DM2NLS9	Approved	Small molecular drug	[2]
Ethanol	DMDRQZU	Approved	Small molecular drug	[3]
Lomefloxacin	DMVRH9C	Approved	Small molecular drug	[4]
Norfloxacin	DMIZ6W2	Approved	Small molecular drug	[5]
Ofloxacin	DM0VQN3	Approved	Small molecular drug	[6]
Sulfacytine	DMKI2XC	Approved	Small molecular drug	[7]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PP-4001	DMDZ45Q	Phase 2	NA	[8]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ReN-1820	DMWIAUK	Terminated	NA	[9]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LP-10	DMLL6CO	Investigative	NA	[10]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 20 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
NAGLU	TTDM6HZ	Limited	Altered Expression	[11]
ADCYAP1	TTW4LYC	Strong	Biomarker	[12]
ADCYAP1R1	TT5OREU	Strong	Biomarker	[13]
BDNF	TTSMLOH	Strong	Altered Expression	[14]
CTH	TTLQUZS	Strong	Altered Expression	[15]
CX3CL1	TT1OFBQ	Strong	Biomarker	[16]
CX3CR1	TT2T98G	Strong	Biomarker	[16]
IL11	TTGUYTR	Strong	Therapeutic	[17]
IL18	TTRICUF	Strong	Biomarker	[18]
IL2	TTF89GD	Strong	Biomarker	[19]
IL4	TTLGTKB	Strong	Biomarker	[20]
KDR	TTUTJGQ	Strong	Biomarker	[21]
LTA	TTP73TM	Strong	Biomarker	[22]
MIF	TT6804T	Strong	Biomarker	[23]
MPO	TTVCZPI	Strong	Biomarker	[24]
NGF	TTDN3LF	Strong	Biomarker	[25]
NGFR	TTEDJN4	Strong	Biomarker	[26]
POMC	TT21AKM	Strong	Biomarker	[27]
PTGER4	TT79WV3	Strong	Biomarker	[19]
TACR1	TTZPO1L	Strong	Biomarker	[28]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC32A1	DTXQYLR	Limited	Altered Expression	[29]

This Disease Is Related to 20 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CENPV	OTPQ0KT9	Limited	Biomarker	[30]
EMP1	OTSZHUHQ	Limited	Genetic Variation	[31]
HM13	OTGEO1LP	Limited	Biomarker	[32]
HPX	OT14T7Q1	Limited	Biomarker	[33]
IFIT3	OTPGHZB9	Limited	Biomarker	[30]
IMMP1L	OTA6LOLR	Limited	Biomarker	[32]
IMPA1	OTBUVW1Z	Limited	Biomarker	[32]
IREB2	OT747D24	Limited	Genetic Variation	[34]
ITIH4	OT460OO1	Limited	Biomarker	[35]
NAIP	OTLA925F	Limited	Altered Expression	[36]
NBAS	OTW9IBRI	Limited	Altered Expression	[11]
NOP53	OTA2YKO6	Limited	Biomarker	[30]
PRDX6	OTS8KC8A	Limited	Biomarker	[30]
REG3G	OTLIUY8Z	Limited	Altered Expression	[37]
RELB	OTU3QYEF	Limited	Altered Expression	[38]
SCN7A	OTK05PXY	Limited	Altered Expression	[11]
SFXN1	OTL66767	Limited	Biomarker	[39]
SUMF2	OT37I8JL	Limited	Biomarker	[40]
SYF2	OTY2ZW1H	Limited	Biomarker	[30]
RELA	OTUJP9CN	Strong	Altered Expression	[38]

References

• [1] Betaine FDA Label
• [2] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2299).
• [4] Lomefloxacin FDA Label
• [5] Norfloxacin FDA Label
• [6] Ofloxacin FDA Label
• [7] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017569.
• [8] ClinicalTrials.gov (NCT01406587) Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection. U.S. National Institutes of Health.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017720)
• [10] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [11] Urine protein, urine protein to creatinine ratio and N-acetyl--D-glucosaminidase index in cats with idiopathic cystitis vs healthy control cats.J Feline Med Surg. 2017 Aug;19(8):869-875. doi: 10.1177/1098612X16663593. Epub 2016 Aug 18.
• [12] PACAP/PAC1 Expression and Function in Micturition Pathways.J Mol Neurosci. 2019 Jul;68(3):357-367. doi: 10.1007/s12031-018-1170-7. Epub 2018 Sep 27.
• [13] PACAP-mediated ATP release from rat urothelium and regulation of PACAP/VIP and receptor mRNA in micturition pathways after cyclophosphamide (CYP)-induced cystitis.J Mol Neurosci. 2008 Nov;36(1-3):310-20. doi: 10.1007/s12031-008-9104-4. Epub 2008 Jun 19.
• [14] Biomarkers in overactive bladder.Int Urogynecol J. 2013 Jul;24(7):1065-72. doi: 10.1007/s00192-012-2027-1. Epub 2013 Jan 12.
• [15] Involvement of NF-B in the upregulation of cystathionine--lyase, a hydrogen sulfide-forming enzyme, and bladder pain accompanying cystitis in mice.Clin Exp Pharmacol Physiol. 2018 Apr;45(4):355-361. doi: 10.1111/1440-1681.12875. Epub 2017 Dec 11.
• [16] Expression of fractalkine and fractalkine receptor in urinary bladder after cyclophosphamide (CYP)-induced cystitis.Auton Neurosci. 2006 Jun 30;126-127:380-9. doi: 10.1016/j.autneu.2006.02.030. Epub 2006 May 2.
• [17] Interleukin-11 attenuates ifosfamide-induced hemorrhagic cystitis.Int Braz J Urol. 2007 Sep-Oct;33(5):704-10. doi: 10.1590/s1677-55382007000500013.
• [18] Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis.Urology. 2009 Feb;73(2):421-6. doi: 10.1016/j.urology.2008.07.031. Epub 2008 Oct 9.
• [19] Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis.Neurourol Urodyn. 2011 Mar;30(3):421-7. doi: 10.1002/nau.20981. Epub 2010 Sep 21.
• [20] IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways.Sci Rep. 2019 Feb 7;9(1):1586. doi: 10.1038/s41598-018-38274-z.
• [21] Functional effects of blocking VEGF/VEGFR2 signaling in the rat urinary bladder in acute and chronic CYP-induced cystitis.Am J Physiol Renal Physiol. 2019 Jul 1;317(7):F43-F51. doi: 10.1152/ajprenal.00083.2019. Epub 2019 Apr 17.
• [22] Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis.Physiol Genomics. 2002;9(1):5-13. doi: 10.1152/physiolgenomics.00117.2001.
• [23] Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association.PLoS One. 2008;3(12):e3898. doi: 10.1371/journal.pone.0003898. Epub 2008 Dec 10.
• [24] [Changes in nitric oxide, prostaglandins and myeloperoxidase activity in acrolein-induced cystitis in rats].Invest Clin. 2009 Mar;50(1):23-33.
• [25] Partners in Crime: NGF and BDNF in Visceral Dysfunction.Curr Neuropharmacol. 2019;17(11):1021-1038. doi: 10.2174/1570159X17666190617095844.
• [26] p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide-induced cystitis.J Comp Neurol. 2008 Mar 20;507(3):1379-92. doi: 10.1002/cne.21627.
• [27] Urinary bladder complications with cyclophosphamide therapy.Arch Intern Med. 1976 May;136(5):616-9.
• [28] The Effects of Neurokinin-1 Receptor Antagonist in an Experimental Autoimmune Cystitis Model Resembling Bladder Pain Syndrome/Interstitial Cystitis.Inflammation. 2019 Feb;42(1):246-254. doi: 10.1007/s10753-018-0888-2.
• [29] MicroRNA-mediated downregulation of potassium-chloride-cotransporter and vesicular -aminobutyric acid transporter expression in spinal cord contributes to neonatal cystitis-induced visceral pain in rats.Pain. 2017 Dec;158(12):2461-2474. doi: 10.1097/j.pain.0000000000001057.
• [30] MicroRNA-mediated GABA A-1 receptor subunit down-regulation in adult spinal cord following neonatal cystitis-induced chronic visceral pain in rats.Pain. 2013 Jan;154(1):59-70. doi: 10.1016/j.pain.2012.09.002.
• [31] Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis.Antimicrob Agents Chemother. 2008 Mar;52(3):846-51. doi: 10.1128/AAC.01200-07. Epub 2007 Dec 17.
• [32] Analysis of IMP-1 type metallo--lactamase-producing Acinetobacter radioresistens isolated from companion animals.J Infect Chemother. 2017 Sep;23(9):655-657. doi: 10.1016/j.jiac.2017.03.011. Epub 2017 Apr 10.
• [33] Intravesical administration of blebbistatin prevents cyclophosphamide-induced toxicity of the urinary bladder in female Wistar rats.Neurourol Urodyn. 2019 Apr;38(4):1044-1052. doi: 10.1002/nau.23973. Epub 2019 Mar 14.
• [34] Contribution of yersiniabactin to the virulence of an Escherichia coli sequence type 69 ("clonal group A") cystitis isolate in murine models of urinary tract infection and sepsis.Microb Pathog. 2018 Jul;120:128-131. doi: 10.1016/j.micpath.2018.04.048. Epub 2018 Apr 24.
• [35] Proteomic techniques identify urine proteins that differentiate patients with interstitial cystitis from asymptomatic control subjects.Am J Obstet Gynecol. 2008 May;198(5):553.e1-6. doi: 10.1016/j.ajog.2008.01.052.
• [36] Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA.Urol Oncol. 2015 Dec;33(12):505.e1-7. doi: 10.1016/j.urolonc.2015.07.012. Epub 2015 Aug 15.
• [37] Expression and Significance of the HIP/PAP and RegIII Antimicrobial Peptides during Mammalian Urinary Tract Infection.PLoS One. 2015 Dec 10;10(12):e0144024. doi: 10.1371/journal.pone.0144024. eCollection 2015.
• [38] Lymphotoxin receptor activation promotes bladder cancer in a nuclear factor-B-dependent manner.Mol Med Rep. 2015 Feb;11(2):783-90. doi: 10.3892/mmr.2014.2826. Epub 2014 Oct 30.
• [39] Is there a correlation between HPV and urinary bladder carcinoma?.Biomed Pharmacother. 2013 Apr;67(3):183-91. doi: 10.1016/j.biopha.2012.10.019. Epub 2012 Dec 7.
• [40] UPEC strain characterization isolated from Mexican patients with recurrent urinary infections.J Infect Dev Ctries. 2016 Apr 28;10(4):317-28. doi: 10.3855/jidc.6652.